COVID-19 Resources

There are so many news stories and stories on social media, it’s hard to keep up and know where to go for reliable information.  We link to the CDC website from komen.org for immediate access to the latest information as it is posted by the CDC – https://ww5.komen.org/BreastCancer/coronavirus-information/

You can also monitor our Newsroom as we post press releases – https://ww5.komen.org/Newsroom/

The Komen Breast Care Helpline 1 877 GO KOMEN (1-877-465-6636) can provide information, psychosocial support and help with coping strategies related to anxiety or concerns during these uncertain times. The service is offered in English and Spanish from 9:00a.m. – 10:00p.m. ET. You can also email the helpline at helpline@komen.org

Here are additional resources from trusted sources you may find helpful.  Keep in mind this is a rapidly evolving situation and some of this information is likely to change.

• CDC: Coronavirus (COVID-19): https://www.cdc.gov/coronavirus/2019-nCoV/index.html

• ACS: Common Questions About the New Coronavirus Outbreak: https://www.cancer.org/latest-news/common-questions-about-the-new-coronavirus-outbreak.html

• NCI: Coronavirus: What People with Cancer Should Know: https://www.cancer.gov/contact/emergency-preparedness/coronavirus?cid=eb_govdel

• ASCO Coronavirus Resources: https://www.asco.org/asco-coronavirus-information

• FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic: https://www.fda.gov/media/136238/download

The FDA today issued a guidance for industry, investigators and institutional review boards conducting clinical trials during the coronavirus (COVID-19) pandemic. The FDA recognizes that the COVID-19 pandemic may impact the conduct of clinical trials of medical products, including drugs, devices and biological products.  Challenges may arise, for example, from quarantines, site closures, travel limitations, interruptions to the supply chain for the investigational product, or other considerations if site personnel or trial subjects become infected with SARS-CoV-2, the virus that causes COVID-19. These challenges may lead to difficulties in conducting clinical trials. The FDA is aware that protocol modifications may be required, and that there may be unavoidable protocol deviations due to COVID-19.  Although the impact of COVID-19 on trials will vary depending on many factors, including the nature of disease under study, the trial design and in what region(s) the study is being conducted, the FDA outlines considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice and minimizing risks to trial integrity.

• JNCCN: How to Manage Cancer Care during COVID-19 Pandemic: https://jnccn.org/fileasset/jnccn1804-Ueda_20118_preprint.pdf

Experts from the Seattle Cancer Care Alliance (SCCA)—a Member Institution of the National Comprehensive Cancer Network® (NCCN®) are sharing insights and advice on how to continue providing optimal cancer care during the novel coronavirus (COVID-19) pandemic. SCCA includes the Fred Hutchinson Cancer Research Center and the University of Washington, which are located in the epicenter of the COVID-19 outbreak in the United States.

• Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. Click here.

The global impact of COVID-19 has been profound, and the public health threat it represents is the most serious seen in a respiratory virus since the 1918 H1N1 influenza pandemic. Here we present the results of epidemiological modeling which has informed policymaking in the UK and other countries in recent weeks. In the absence of a COVID-19 vaccine, we assess the potential role of a number of public health measures – so-called non-pharmaceutical interventions (NPIs) – aimed at reducing contact rates in the population and thereby reducing transmission of the virus. In the results presented here, we apply a previously published microsimulation model to two countries: the UK (Great Britain specifically) and the US. We conclude that the effectiveness of any one intervention in isolation is likely to be limited, requiring multiple interventions to be combined to have a substantial impact on transmission.

• MQSA Inspection Information Related to COVID-19. Click here.

• New England Journal of Medicine: https://www.nejm.org/coronavirus?query=RP

A special page at NEJM.org presents a collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary. All articles are freely available.

Go to Top